Biofrontera (BFRI) Revenue (2020 - 2025)

Biofrontera's Revenue history runs 6 years deep, the most recent figure standing at $17.1 million for Q4 2025.

• On a quarterly basis, Revenue rose 36.16% year-over-year to $17.1 million in Q4 2025; TTM through Dec 2025 was $41.7 million, a 11.75% increase from a year earlier, with the FY2025 full-year figure at $41.7 million, up 11.75% from the prior year.
• Revenue grew to $17.1 million in Q4 2025 per BFRI's latest filing, from $7.0 million in the prior quarter.
• Across five years, Revenue topped out at $17.1 million in Q4 2025 and bottomed at -$14.9 million in Q4 2021.
• The 5-year median for Revenue is $8.2 million (2024), against an average of $7.1 million.
• Across the five-year window, Revenue sank 273.53% in 2021 and surged 168.19% in 2022, its largest moves.
• Year by year, Revenue stood at -$14.9 million in 2021, then surged by 168.19% to $10.1 million in 2022, then increased by 4.46% to $10.6 million in 2023, then climbed by 18.53% to $12.6 million in 2024, then jumped by 36.16% to $17.1 million in 2025.
• Per Business Quant, the three latest BFRI Revenue figures stand at $17.1 million (Q4 2025), $7.0 million (Q3 2025), and $9.0 million (Q2 2025).